Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof

US12077572B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• KOREA (CENTER FOR DISEASE CONTROL AND PREVENTION) · KR

Inventors

• Hansaem Lee · Mongchon-ri, KR
• Janghoon Choi · Mongchon-ri, KR
• Sungsoon Kim · Ulsan, KR
• Lingshu Wang · North Potomac, US
• Barney Graham · Rockville, US
• John Mascola · Rockville, US

Key dates

• Filing date: Sep 25, 2022
• Grant date: Sep 3, 2024
• Expiry date: Jan 26, 2043

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2469/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the S1 domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.